{"id":71866,"date":"2026-08-07T20:17:30","date_gmt":"2026-08-07T12:17:30","guid":{"rendered":"https:\/\/flcube.com\/?p=71866"},"modified":"2026-08-07T20:17:32","modified_gmt":"2026-08-07T12:17:32","slug":"merck-secures-fda-acceptance-for-enflonsia-sbla-to-expand-rsv-prevention-through-second-season-in-high-risk-children","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=71866","title":{"rendered":"Merck Secures FDA Acceptance for Enflonsia sBLA to Expand RSV Prevention Through Second Season in High-Risk Children"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Merck &amp; Co., Inc.<\/strong> (MSD, <a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/MRK:NYSE\">NYSE: MRK<\/a>) announced that the U.S. <strong>Food and Drug Administration (FDA)<\/strong> has accepted a <strong>supplemental Biologics License Application (sBLA)<\/strong> for <strong>Enflonsia (clesrovimab-cfor)<\/strong> to expand its indication for the prevention of <strong>respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD)<\/strong> in children under two years of age at increased risk for severe RSV disease through their second RSV season.<\/p>\n\n\n\n<h2 id=\"h-regulatory-timeline-amp-status\" class=\"wp-block-heading\">Regulatory Timeline &amp; Status<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>FDA (U.S.) \/ EMA (EU)<\/td><\/tr><tr><td><strong>Application Type<\/strong><\/td><td>Supplemental Biologics License Application (sBLA)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Enflonsia (clesrovimab-cfor)<\/td><\/tr><tr><td><strong>Expanded Indication<\/strong><\/td><td>Prevention of RSV LRTD in high-risk children &lt;2 years through second RSV season<\/td><\/tr><tr><td><strong>FDA PDUFA Date<\/strong><\/td><td>March 22, 2027<\/td><\/tr><tr><td><strong>EMA Status<\/strong><\/td><td>Application accepted July 2026<\/td><\/tr><tr><td><strong>Current Approvals<\/strong><\/td><td>FDA: June 2025; European Commission: April 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profile-amp-differentiation\" class=\"wp-block-heading\">Product Profile &amp; Differentiation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Extended half-life monoclonal antibody (mAb)<\/li>\n\n\n\n<li><strong>Administration:<\/strong> Single-dose injection without weight-based dosing requirements<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> First and only RSV preventive option that eliminates complex weight-based dosing calculations<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Passive immunization specifically targeting RSV to prevent lower respiratory tract disease<\/li>\n\n\n\n<li><strong>Current Use:<\/strong> Approved for infants born during or entering their first RSV season<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-amp-commercial-significance\" class=\"wp-block-heading\">Clinical &amp; Commercial Significance<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Respiratory syncytial virus represents a significant burden on pediatric healthcare systems globally, with high-risk children remaining vulnerable beyond their first year of life. The expanded indication would address a critical unmet need for continued protection through the second RSV season, when many high-risk children remain susceptible to severe complications.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Enflonsia&#8217;s weight-independent dosing protocol offers substantial operational advantages for healthcare providers compared to existing RSV preventive options that require precise weight-based calculations. This streamlined approach could improve vaccination coverage rates and reduce administrative barriers in clinical settings.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-outlook\" class=\"wp-block-heading\">Market Impact &amp; Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Addressable Population:<\/strong> Millions of high-risk children under two years who remain vulnerable through their second RSV season<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Enflonsia would be the only approved option offering extended protection without weight-based dosing complexity<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Successful expansion could significantly increase Merck&#8217;s addressable market in the growing RSV prevention segment<\/li>\n\n\n\n<li><strong>Global Strategy:<\/strong> Parallel regulatory progress in both U.S. and EU markets demonstrates Merck&#8217;s coordinated global development approach<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory timelines and commercial expectations for Enflonsia. Actual results may differ due to risks including final regulatory decisions, market adoption, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck &amp; Co., Inc. (MSD, NYSE: MRK) announced that the U.S. Food and Drug Administration&#8230;<\/p>\n","protected":false},"author":1,"featured_media":71944,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[1],"tags":[120,2675,176,903],"class_list":["post-71866","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","tag-merck","tag-merck-sharp-dohme","tag-msd","tag-nyse-mrk"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Merck Secures FDA Acceptance for Enflonsia sBLA to Expand RSV Prevention Through Second Season in High-Risk Children - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Merck &amp; Co., Inc. (MSD, NYSE: MRK) announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for Enflonsia (clesrovimab-cfor) to expand its indication for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in children under two years of age at increased risk for severe RSV disease through their second RSV season.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=71866\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Secures FDA Acceptance for Enflonsia sBLA to Expand RSV Prevention Through Second Season in High-Risk Children\" \/>\n<meta property=\"og:description\" content=\"Merck &amp; Co., Inc. (MSD, NYSE: MRK) announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for Enflonsia (clesrovimab-cfor) to expand its indication for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in children under two years of age at increased risk for severe RSV disease through their second RSV season.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=71866\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-07T12:17:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-07T12:17:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0701.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71866#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71866\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Merck Secures FDA Acceptance for Enflonsia sBLA to Expand RSV Prevention Through Second Season in High-Risk Children\",\"datePublished\":\"2026-08-07T12:17:30+00:00\",\"dateModified\":\"2026-08-07T12:17:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71866\"},\"wordCount\":389,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71866#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0701.webp\",\"keywords\":[\"Merck\",\"Merck Sharp &amp; Dohme\",\"MSD\",\"NYSE: MRK\"],\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71866#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71866\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=71866\",\"name\":\"Merck Secures FDA Acceptance for Enflonsia sBLA to Expand RSV Prevention Through Second Season in High-Risk Children - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71866#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71866#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0701.webp\",\"datePublished\":\"2026-08-07T12:17:30+00:00\",\"dateModified\":\"2026-08-07T12:17:32+00:00\",\"description\":\"Merck & Co., Inc. (MSD, NYSE: MRK) announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for Enflonsia (clesrovimab-cfor) to expand its indication for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in children under two years of age at increased risk for severe RSV disease through their second RSV season.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71866#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71866\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71866#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0701.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0701.webp\",\"width\":1080,\"height\":608,\"caption\":\"Merck Secures FDA Acceptance for Enflonsia sBLA to Expand RSV Prevention Through Second Season in High-Risk Children\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71866#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Secures FDA Acceptance for Enflonsia sBLA to Expand RSV Prevention Through Second Season in High-Risk Children\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Merck Secures FDA Acceptance for Enflonsia sBLA to Expand RSV Prevention Through Second Season in High-Risk Children - Insight, China&#039;s Pharmaceutical Industry","description":"Merck & Co., Inc. (MSD, NYSE: MRK) announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for Enflonsia (clesrovimab-cfor) to expand its indication for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in children under two years of age at increased risk for severe RSV disease through their second RSV season.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=71866","og_locale":"en_US","og_type":"article","og_title":"Merck Secures FDA Acceptance for Enflonsia sBLA to Expand RSV Prevention Through Second Season in High-Risk Children","og_description":"Merck & Co., Inc. (MSD, NYSE: MRK) announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for Enflonsia (clesrovimab-cfor) to expand its indication for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in children under two years of age at increased risk for severe RSV disease through their second RSV season.","og_url":"https:\/\/flcube.com\/?p=71866","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-07T12:17:30+00:00","article_modified_time":"2026-08-07T12:17:32+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0701.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=71866#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=71866"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Merck Secures FDA Acceptance for Enflonsia sBLA to Expand RSV Prevention Through Second Season in High-Risk Children","datePublished":"2026-08-07T12:17:30+00:00","dateModified":"2026-08-07T12:17:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=71866"},"wordCount":389,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=71866#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0701.webp","keywords":["Merck","Merck Sharp &amp; Dohme","MSD","NYSE: MRK"],"articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=71866#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=71866","url":"https:\/\/flcube.com\/?p=71866","name":"Merck Secures FDA Acceptance for Enflonsia sBLA to Expand RSV Prevention Through Second Season in High-Risk Children - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=71866#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=71866#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0701.webp","datePublished":"2026-08-07T12:17:30+00:00","dateModified":"2026-08-07T12:17:32+00:00","description":"Merck & Co., Inc. (MSD, NYSE: MRK) announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for Enflonsia (clesrovimab-cfor) to expand its indication for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in children under two years of age at increased risk for severe RSV disease through their second RSV season.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=71866#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=71866"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=71866#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0701.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0701.webp","width":1080,"height":608,"caption":"Merck Secures FDA Acceptance for Enflonsia sBLA to Expand RSV Prevention Through Second Season in High-Risk Children"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=71866#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Merck Secures FDA Acceptance for Enflonsia sBLA to Expand RSV Prevention Through Second Season in High-Risk Children"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0701.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71866","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=71866"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71866\/revisions"}],"predecessor-version":[{"id":71943,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71866\/revisions\/71943"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/71944"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=71866"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=71866"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=71866"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}